Published in J Clin Invest on January 01, 2002
Mechanisms for pituitary tumorigenesis: the plastic pituitary. J Clin Invest (2003) 2.18
Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene. Endocr Rev (2013) 1.40
Pituitary hypoplasia in Pttg-/- mice is protective for Rb+/- pituitary tumorigenesis. Mol Endocrinol (2005) 1.40
Regulation of angiogenesis and invasion by human Pituitary tumor transforming gene (PTTG) through increased expression and secretion of matrix metalloproteinase-2 (MMP-2). Mol Cancer (2006) 1.07
Pituitary tumor transforming gene binding factor: a new gene in breast cancer. Cancer Res (2010) 1.02
PTTG: an important target gene for ovarian cancer therapy. J Ovarian Res (2008) 1.01
The emerging role of pituitary tumor transforming gene in tumorigenesis. Clin Med Res (2006) 0.92
Thrombospondin-1 (TSP-1) analogs ABT-510 and ABT-898 inhibit prolactinoma growth and recover active pituitary transforming growth factor-β1 (TGF-β1). Endocrinology (2012) 0.88
Pituitary tumors. Endocrinol Metab Clin North Am (2015) 0.85
Genetic control of estrogen action in the rat: mapping of QTLs that impact pituitary lactotroph hyperplasia in a BN x ACI intercross. Mamm Genome (2007) 0.85
Effect of PTTG on endogenous gene expression in HEK 293 cells. BMC Genomics (2009) 0.81
Subchronic exposure to phytoestrogens alone and in combination with diethylstilbestrol - pituitary tumor induction in Fischer 344 rats. Nutr Metab (Lond) (2010) 0.81
Pregnancy and pituitary disorders: Challenges in diagnosis and management. Indian J Endocrinol Metab (2013) 0.81
PTTG expression in different experimental and human prolactinomas in relation to dopaminergic control of lactotropes. Mol Cancer (2007) 0.80
Correlations of pituitary tumor transforming gene expression with human pituitary adenomas: a meta-analysis. PLoS One (2014) 0.79
Effects of resveratrol on cell growth and prolactin synthesis in GH3 cells. Exp Ther Med (2014) 0.79
Genomic characterization of human and rat prolactinomas. Endocrinology (2012) 0.79
Gene therapy for pituitary tumors. Curr Gene Ther (2005) 0.78
Enhanced LH action in transgenic female mice expressing hCGbeta-subunit induces pituitary prolactinomas; the role of high progesterone levels. Endocr Relat Cancer (2010) 0.78
Inhibition of SKP2 Sensitizes Bromocriptine-Induced Apoptosis in Human Prolactinoma Cells. Cancer Res Treat (2016) 0.77
Angiogenesis in pituitary adenomas: human studies and new mutant mouse models. Int J Endocrinol (2014) 0.77
Pituitary hyperplasia: case series and literature review of an under-recognised and heterogeneous condition. Endocrinol Diabetes Metab Case Rep (2015) 0.76
Estradiol partially recapitulates murine pituitary cell cycle response to pregnancy. Endocrinology (2012) 0.76
Animal models for aberrations of gonadotropin action. Rev Endocr Metab Disord (2011) 0.76
Systemic therapy of Cushing's syndrome. Orphanet J Rare Dis (2014) 0.76
Subcellular localisation of VEGF in different pituitary cells. Changes of its expression in oestrogen induced prolactinomas. J Mol Histol (2006) 0.76
Down-regulation of the oncogene PTTG1 via the KLF6 tumor suppressor during induction of myeloid differentiation. PLoS One (2013) 0.76
Securin promotes the identification of favourable outcome in invasive breast cancer. Br J Cancer (2009) 0.76
The pituitary TGFβ1 system as a novel target for the treatment of resistant prolactinomas. J Endocrinol (2015) 0.76
Short-term pharmacological suppression of the hyperprolactinemia of infertile hCG-overproducing female mice persistently restores their fertility. Endocrinology (2012) 0.76
Voluntary wheel running mitigates the stress-induced bone loss in ovariectomized rats. J Bone Miner Metab (2014) 0.76
Pituitary Medicine From Discovery to Patient-Focused Outcomes. J Clin Endocrinol Metab (2016) 0.75
N-myc downstream-regulated gene 2 (NDRG2) promoter methylation and expression in pituitary adenoma. Diagn Pathol (2017) 0.75
Stress-reactive rats (high-avoidance female rats) have a shorter lifespan than stress-nonreactive rats (low-avoidance female rats). J Toxicol Pathol (2015) 0.75
The involvement of angiotensin type 1 and type 2 receptors in estrogen-induced cell proliferation and vascular endothelial growth factor expression in the rat anterior pituitary. ScientificWorldJournal (2012) 0.75
Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis. Science (1999) 6.07
The multifaceted mechanisms of estradiol and estrogen receptor signaling. J Biol Chem (2001) 4.67
A potent specific pure antiestrogen with clinical potential. Cancer Res (1991) 3.54
Isolation and characterization of a pituitary tumor-transforming gene (PTTG). Mol Endocrinol (1997) 2.90
Expression of pituitary-tumour transforming gene in colorectal tumours. Lancet (2000) 2.39
17beta-estradiol inhibits apoptosis in MCF-7 cells, inducing bcl-2 expression via two estrogen-responsive elements present in the coding sequence. Mol Cell Biol (2000) 1.83
Structure, expression, and function of human pituitary tumor-transforming gene (PTTG). Mol Endocrinol (1999) 1.78
Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis. Nat Med (1999) 1.72
Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas. J Clin Endocrinol Metab (1999) 1.69
Role of estrogen receptor-alpha in the anterior pituitary gland. Mol Endocrinol (1997) 1.29
Pituitary tumor transforming gene causes aneuploidy and p53-dependent and p53-independent apoptosis. J Biol Chem (2000) 1.24
Estradiol regulates the transcription of the prolactin gene. J Biol Chem (1982) 1.21
Human pituitary tumor-transforming gene induces angiogenesis. J Clin Endocrinol Metab (2001) 1.17
Management of prolactinomas during pregnancy. J Reprod Med (1999) 1.14
Estrogen control of prolactin synthesis in vitro. Proc Natl Acad Sci U S A (1978) 1.12
Pituitary tumor transforming gene (PTTG) regulates placental JEG-3 cell division and survival: evidence from live cell imaging. Mol Endocrinol (2000) 1.05
Transforming events in thyroid tumorigenesis and their association with follicular lesions. J Clin Endocrinol Metab (2001) 1.00
Estrogen-induced prolactinoma in a man. J Clin Endocrinol Metab (1988) 1.00
A nonmitogenic pituitary function of fibroblast growth factor: regulation of thyrotropin and prolactin secretion. Proc Natl Acad Sci U S A (1985) 0.98
Identification of the human pituitary tumor transforming gene (hPTTG) family: molecular structure, expression, and chromosomal localization. Gene (2000) 0.94
Prolactin-producing pituitary adenoma in a male-to-female transsexual patient with protracted estrogen administration. A morphologic study. Arch Pathol Lab Med (1994) 0.93
Anti-proliferative and anti-estrogenic effects of ICI 164,384 and ICI 182,780 in 4-OH-tamoxifen-resistant human breast-cancer cells. Int J Cancer (1994) 0.91
Estrogens and the genetic control of tumor growth. Prog Clin Biol Res (1997) 0.91
Differential expression of estrogen receptor-beta (ER beta) in human pituitary tumors: functional interactions with ER alpha and a tumor-specific splice variant. J Clin Endocrinol Metab (1998) 0.90
Dominant negative ER induces apoptosis in GH(4) pituitary lactotrope cells and inhibits tumor growth in nude mice. Endocrinology (2001) 0.89
Pentobarbital anesthesia during the proestrous afternoon blocks lactotroph proliferation occurring on estrus in female rats. Endocrinology (1995) 0.88
In situ hybridization study of estrogen receptor messenger ribonucleic acid in human adenohypophysial cells and pituitary adenomas. J Clin Endocrinol Metab (1994) 0.87
Cellular proliferation in the anterior pituitary gland of normal adult rats: influences of sex, estrous cycle, and circadian change. Anat Rec (1993) 0.87
Cyclical endometrial steroid hormone receptor expression and proliferation intensity in the mare. Equine Vet J (2000) 0.87
An intronless homolog of human proto-oncogene hPTTG is expressed in pituitary tumors: evidence for hPTTG family. J Clin Endocrinol Metab (1999) 0.87
Oral contraceptives and pituitary adenomas. Br Med J (1980) 0.86
Cell-specific expression of estrogen receptor in the human pituitary and its adenomas. J Clin Endocrinol Metab (1995) 0.85
Differential regulation of prolactin release and lactotrope proliferation during pregnancy, lactation and the estrous cycle. Neuroendocrinology (2000) 0.85
Cellular receptors for sex steroids in human pituitary adenomas. J Endocrinol (1996) 0.85
Enzyme-immunoassay for estrogen receptors in human pituitary adenomas. Acta Endocrinol (Copenh) (1989) 0.84
The effect of GH on estrogen receptor expression in the rat mammary gland. J Endocrinol (1999) 0.84
Tamoxifen suppresses both the growth of prolactin-secreting pituitary tumours and normal prolactin synthesis in the rat. J Endocrinol (1980) 0.83
Expression of bcl-2 oncoprotein in pituitary tumours: comparison with c-myc. J Clin Pathol (1996) 0.83
Catechol estrogens: presence in brain and endocrine tissues. Science (1977) 0.81
Relation of circulating estradiol and progesterone to gonadotropin secretion and estrous cyclicity in aging female rats. Endocrinology (1985) 0.81
Lactotroph hyperplasia in an estrogen treated male-to-female transsexual patient. J Clin Endocrinol Metab (1996) 0.81
Poly (adenosine diphosphate-ribose) synthesis in the anterior pituitary of the female rat throughout the estrous cycle: study of possible relation to cell proliferation and prolactin gene expression. J Endocrinol Invest (1993) 0.80
Estrogen receptor blockade by the pure antiestrogen, ZM 182780, induces death of pituitary tumour cells. J Steroid Biochem Mol Biol (1995) 0.80
Prolactinoma. Curr Ther Endocrinol Metab (1997) 0.79
Formation of 2- and 4-hydroxyestrogens by brain, pituitary, and liver of the human fetus. J Clin Endocrinol Metab (1978) 0.79
The effect of tamoxifen on GH and PRL secretion by human pituitary tumors. J Endocrinol Invest (1981) 0.79
Effects of estrogen on the human pituitary: a clinicopathologic study. Mayo Clin Proc (1989) 0.79
Antagonism by progesterone of diethylstilbestrol-induced pituitary tumorigenesis in Fischer 344 rats: effects on sex steroid receptors and tyrosine hydroxylase mRNA. Neuroendocrinology (1996) 0.79
Changes in content of prolactin mRNA during the rat estrous cycle. Exp Clin Endocrinol (1990) 0.77
Ornithine decarboxylase activity and polyamines in the anterior pituitary gland during the rat oestrous cycle. J Endocrinol (1985) 0.77
Studies on the effects of catecholestrogens on prolactin secretion by cultured normal rat anterior pituitary cells. Endocrinology (1985) 0.77
Radioimmunoassay of 2-hydroxyestrone in plasma during the estrous cycle of the rat: interrelationships with estradiol, progesterone, and the gonadotropins. Endocrinology (1983) 0.77
2-Hydroxylation of estrogens in the brain participates in the initiation of the preovulatory LH surge in the rat. Biochem Biophys Res Commun (1980) 0.77
Urinary excretion pattern of catecholestrogens in preovulatory LH surge during the 4-day estrous cycle of rats. J Endocrinol Invest (2001) 0.76
Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab (2012) 2.87
STK33 kinase activity is nonessential in KRAS-dependent cancer cells. Cancer Res (2011) 2.29
Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab (2014) 2.01
Elucidating the murine brain transcriptional network in a segregating mouse population to identify core functional modules for obesity and diabetes. J Neurochem (2006) 2.00
Pituitary tumor-transforming gene: physiology and implications for tumorigenesis. Endocr Rev (2007) 1.79
Angiogenesis in endocrine tumors. Endocr Rev (2003) 1.50
EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas. J Clin Invest (2011) 1.49
Pituitary hypoplasia in Pttg-/- mice is protective for Rb+/- pituitary tumorigenesis. Mol Endocrinol (2005) 1.40
Pituitary magnetic resonance imaging for sellar and parasellar masses: ten-year experience in 2598 patients. J Clin Endocrinol Metab (2011) 1.34
p21(Cip1) restrains pituitary tumor growth. Proc Natl Acad Sci U S A (2008) 1.31
Overexpressed pituitary tumor-transforming gene causes aneuploidy in live human cells. Endocrinology (2003) 1.29
Acromegaly. Endocrinol Metab Clin North Am (2008) 1.23
A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. J Clin Endocrinol Metab (2008) 1.19
Pituitary tumor transforming gene-null male mice exhibit impaired pancreatic beta cell proliferation and diabetes. Proc Natl Acad Sci U S A (2003) 1.19
PPAR-gamma receptor ligands: novel therapy for pituitary adenomas. J Clin Invest (2003) 1.18
Early multipotential pituitary focal hyperplasia in the alpha-subunit of glycoprotein hormone-driven pituitary tumor-transforming gene transgenic mice. Mol Endocrinol (2005) 1.18
Body mass index determines evoked growth hormone (GH) responsiveness in normal healthy male subjects: diagnostic caveat for adult GH deficiency. J Clin Endocrinol Metab (2004) 1.15
Molecular targets in pituitary tumours. Nat Rev Cancer (2004) 1.14
The neuroprotective WldS gene regulates expression of PTTG1 and erythroid differentiation regulator 1-like gene in mice and human cells. Hum Mol Genet (2006) 1.14
Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Nat Med (2002) 1.14
Senescence mediates pituitary hypoplasia and restrains pituitary tumor growth. Cancer Res (2007) 1.09
Pituitary corticotroph ontogeny and regulation in transgenic zebrafish. Mol Endocrinol (2003) 1.09
Single-surgeon fully endoscopic endonasal transsphenoidal surgery: outcomes in three-hundred consecutive cases. Pituitary (2013) 1.08
The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly. J Clin Endocrinol Metab (2008) 1.08
Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis. J Clin Invest (2004) 1.06
Targeting zebrafish and murine pituitary corticotroph tumors with a cyclin-dependent kinase (CDK) inhibitor. Proc Natl Acad Sci U S A (2011) 1.05
Ectopic acromegaly due to growth hormone releasing hormone. Endocrine (2012) 1.05
Meta-analysis on the effects of octreotide on tumor mass in acromegaly. PLoS One (2012) 1.05
Minireview: Neuro-immuno-endocrine modulation of the hypothalamic-pituitary-adrenal (HPA) axis by gp130 signaling molecules. Endocrinology (2002) 1.04
Selective and potent Raf inhibitors paradoxically stimulate normal cell proliferation and tumor growth. Mol Cancer Ther (2010) 1.04
Pituitary somatostatin receptor signaling. Trends Endocrinol Metab (2010) 1.03
Lipodystrophy in patients with acromegaly receiving pegvisomant. J Clin Endocrinol Metab (2008) 1.03
Pituitary tumor transforming gene overexpression facilitates pituitary tumor development. Endocrinology (2006) 1.02
Securin is overexpressed in breast cancer. Mod Pathol (2005) 1.02
Rat prolactinoma cell growth regulation by epidermal growth factor receptor ligands. Cancer Res (2008) 0.98
Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis. J Clin Endocrinol Metab (2014) 0.96
Lineage-specific restraint of pituitary gonadotroph cell adenoma growth. PLoS One (2011) 0.95
A botulinum toxin-derived targeted secretion inhibitor downregulates the GH/IGF1 axis. J Clin Invest (2012) 0.94
Growth hormone is a cellular senescence target in pituitary and nonpituitary cells. Proc Natl Acad Sci U S A (2013) 0.93
Somatostatin agonists for treatment of acromegaly. Mol Cell Endocrinol (2007) 0.92
Zebrafish usp39 mutation leads to rb1 mRNA splicing defect and pituitary lineage expansion. PLoS Genet (2011) 0.92
Acromegaly with moderate hyperprolactinemia caused by an intrasellar macroadenoma. Nat Clin Pract Endocrinol Metab (2006) 0.90
Ovarian hyperstimulation syndrome caused by an FSH-secreting pituitary adenoma. Nat Clin Pract Endocrinol Metab (2008) 0.90
HER2/ErbB2 receptor signaling in rat and human prolactinoma cells: strategy for targeted prolactinoma therapy. Mol Endocrinol (2010) 0.90
Regulation of growth hormone and prolactin gene expression and secretion by chimeric somatostatin-dopamine molecules. Endocrinology (2007) 0.89
Aryl hydrocarbon receptor interacting protein variants in sporadic pituitary adenomas. J Clin Endocrinol Metab (2006) 0.89
Prolactin receptor signaling mediates the osmotic response of embryonic zebrafish lactotrophs. Mol Endocrinol (2005) 0.89
Optimizing control of acromegaly: integrating a growth hormone receptor antagonist into the treatment algorithm. J Clin Endocrinol Metab (2003) 0.89
Silent corticogonadotroph adenomas: clinical and cellular characteristics and long-term outcomes. Horm Cancer (2010) 0.88
Subclinical hyperfunctioning pituitary adenomas: the silent tumors. Best Pract Res Clin Endocrinol Metab (2012) 0.88
Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study. Pituitary (2014) 0.87
Heregulin regulates prolactinoma gene expression. Cancer Res (2009) 0.87
Changing patterns of the adult growth hormone deficiency diagnosis documented in a decade-long global surveillance database. J Clin Endocrinol Metab (2008) 0.87
Selective inhibitors of the mutant B-Raf pathway: discovery of a potent and orally bioavailable aminoisoquinoline. J Med Chem (2009) 0.87
Constitutive somatostatin receptor activity determines tonic pituitary cell response. Mol Endocrinol (2009) 0.86
Treatment of acromegaly: future. Endocrine (2005) 0.86
The novel somatostatin ligand (SOM230) regulates human and rat anterior pituitary hormone secretion. J Clin Endocrinol Metab (2004) 0.86
Prospective safety surveillance of GH-deficient adults: comparison of GH-treated vs untreated patients. J Clin Endocrinol Metab (2013) 0.86
Functional association of somatostatin receptor subtypes 2 and 5 in inhibiting human growth hormone secretion. J Clin Endocrinol Metab (2003) 0.86
Selective regulation of somatostatin receptor subtype signaling: evidence for constitutive receptor activation. Mol Endocrinol (2007) 0.85
Metabolic, cardiovascular, and cerebrovascular outcomes in growth hormone-deficient subjects with previous cushing's disease or non-functioning pituitary adenoma. J Clin Endocrinol Metab (2009) 0.85
The cell adhesion molecules N-cadherin and neural cell adhesion molecule regulate human growth hormone: a novel mechanism for regulating pituitary hormone secretion. J Clin Endocrinol Metab (2003) 0.84
Expression and function of ErbB receptors and ligands in the pituitary. Endocr Relat Cancer (2011) 0.84
E2F1 induces pituitary tumor transforming gene (PTTG1) expression in human pituitary tumors. Mol Endocrinol (2009) 0.84
Pituitary tumor transforming gene: an update. Front Horm Res (2004) 0.84
Sca1⁺ murine pituitary adenoma cells show tumor-growth advantage. Endocr Relat Cancer (2014) 0.83
Somatostatin receptor type 5 modulates somatostatin receptor type 2 regulation of adrenocorticotropin secretion. J Biol Chem (2005) 0.83
Discordant proliferation and differentiation in pituitary tumor-transforming gene-null bone marrow stem cells. Am J Physiol Cell Physiol (2007) 0.83
Supplemental growth hormone in healthy adults: the endocrinologist's responsibility. Nat Clin Pract Endocrinol Metab (2006) 0.83
Differential ligand-mediated pituitary somatostatin receptor subtype signaling: implications for corticotroph tumor therapy. J Clin Endocrinol Metab (2009) 0.83
Skin manifestations in acromegaly. Clin Dermatol (2006) 0.83
Pasireotide--a somatostatin analog for the potential treatment of acromegaly, neuroendocrine tumors and Cushing's disease. IDrugs (2007) 0.83
PTTG1 attenuates drug-induced cellular senescence. PLoS One (2011) 0.82
Pituitary tumour-transforming gene (PTTG) and pituitary senescence. Horm Res (2009) 0.82
Human pituitary tumor-transforming gene (PTTG1) motif suppresses prolactin expression. Mol Endocrinol (2003) 0.82
Cell-specific pituitary gene expression profiles after treatment with leukemia inhibitory factor reveal novel modulators for proopiomelanocortin expression. Endocrinology (2003) 0.82
Pituitary senescence: the evolving role of Pttg. Mol Cell Endocrinol (2010) 0.82
A structural and functional acromegaly classification. J Clin Endocrinol Metab (2015) 0.82
Clusterin and FOXL2 act concordantly to regulate pituitary gonadotroph adenoma growth. Mol Endocrinol (2012) 0.81
Suppression of rat and human growth hormone and prolactin secretion by a novel somatostatin/dopaminergic chimeric ligand. J Clin Endocrinol Metab (2003) 0.81
STAT3 upregulation in pituitary somatotroph adenomas induces growth hormone hypersecretion. J Clin Invest (2015) 0.81
Acromegaly consensus: the next steps. J Clin Endocrinol Metab (2003) 0.80
Clinical review 154: The role of pharmacotherapy in perioperative management of patients with acromegaly. J Clin Endocrinol Metab (2003) 0.80
ErbB receptor-driven prolactinomas respond to targeted lapatinib treatment in female transgenic mice. Endocrinology (2015) 0.80
Pituitary adenoma growth: a model for cellular senescence and cytokine action. Cell Cycle (2009) 0.80
Oct-1 induces pituitary tumor transforming gene expression in endocrine tumors. Endocr Relat Cancer (2008) 0.80
Constitutive somatostatin receptor subtype-3 signaling suppresses growth hormone synthesis. Mol Endocrinol (2014) 0.80
Patient guide to hyperprolactinemia diagnosis and treatment. J Clin Endocrinol Metab (2011) 0.80
In vivo time-lapse imaging delineates the zebrafish pituitary proopiomelanocortin lineage boundary regulated by FGF3 signal. Dev Biol (2008) 0.80
Somatostatin analogs and chimeric somatostatin-dopamine molecules differentially regulate human growth hormone and prolactin gene expression and secretion in vitro. Mol Cell Endocrinol (2012) 0.79
The endocrine tumor summit 2008: appraising therapeutic approaches for acromegaly and carcinoid syndrome. Pituitary (2010) 0.79
Constitutive activity of somatostatin receptor subtypes. Methods Enzymol (2010) 0.79
CEBPD suppresses prolactin expression and prolactinoma cell proliferation. Mol Endocrinol (2011) 0.79
Genomic characterization of human and rat prolactinomas. Endocrinology (2012) 0.79
Elevated circulating leukemia inhibitory factor in patients with extensive burns. J Burn Care Res (2006) 0.78
Pathogenesis of pituitary tumors. Prog Brain Res (2010) 0.78
Molecular mechanisms of pituitary adenoma senescence. Front Horm Res (2010) 0.78